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Arsenic  is  a  naturally  occurring  element  that  is  ubiquitously 
present in the environment. High concentration of naturally occur-
ring arsenic in drinking water is a major health problem in different 
parts of the world. Despite arsenic being a health hazard and a 
well documented carcinogen, no safe, effective and specific preven-
tive or therapeutic measures are available. Among various recent 
strategies  adopted,  administration  of  an  antioxidant  has  been 
reported to be the most effective. The present study was designed 
to evaluate the therapeutic efficacy of monoisoamyl dimercapto-
succinic acid (MiADMSA), administered either individually or in 
combination with taurine post chronic arsenic exposure in rats. 
Arsenic exposed male rats (25 ppm, sodium arsenite in drinking 
water for 24 weeks) were treated with taurine (100 mg/kg, i.p., 
once  daily),  monoisoamyl  dimercaptosuccinic  acid  (MiADMSA)   
(50 mg/kg, oral, once daily) either individually or in combination 
for 5 consecutive days. Biochemical variables indicative of oxidative 
stress along-with arsenic concentration in blood, liver and kidney 
were  measured.  Arsenic  exposure  significantly  reduced  blood   
δ-aminolevulinic acid dehydratase (ALAD) activity, a key enzyme 
involved in the heme biosynthesis and enhanced zinc protopor-
phyrin  (ZPP)  level.  Clinical  hematological  variables  like  white 
blood cells (WBC), mean cell hemoglobin (MCH), and mean cell 
hemoglobin concentration (MCHC) showed significant decrease 
with a significant elevation in platelet (PLT) count. These changes 
were accompanied by significant decrease in superoxide dismutase 
(SOD)  activity  and  increased  catalase  activity.  Arsenic  exposure 
caused  a  significant  decrease  in  hepatic  and  renal  glutathione 
(GSH) level and an increase in oxidized glutathione (GSSG). These 
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biochemical changes were correlated with an increased uptake of 
arsenic in blood, liver and kidney. Administration of taurine signifi-
cantly reduced hepatic oxidative stress however co-administration 
of a higher dose of taurine (100 mg/kg) and MiADMSA provided 
more pronounced effects in improving the antioxidant status of 
liver and kidney and reducing body arsenic burden compared to 
the  individual  treatment  of  MiADMSA  or  taurine.  The  results 
suggest that in order to achieve better effects of chelation therapy, 
co-administration of taurine with MiADMSA might be preferred. 
Introduction
The  drinking  water  containing  arsenic  more  than  10  µg/L  is 
harmful to the body.1 The main source of this arsenic contamination 
is the shallow tube wells, having more than 500 µg/L of arsenic.2 
Heavy reliance of agriculture on new water wells has lead to exten-
sive  chronic  arsenic  poisoning  in  certain  parts  of  countries  like 
Bangladesh, India (West Bengal) and China (Inner Mongolia).3,4 In 
addition to the natural sources of arsenic contamination in drinking 
water, use of arsenic-containing herbicides, insecticides, rodenticides, 
preservatives and by-products of fossil fuels are enough to challenge 
the aquatic environment as well as humankind.5 Arsenic induced 
oxidative stress in blood and other soft tissues has been postulated to 
be one of the possible mechanisms of arsenic induced toxic effects.6-9 
Disruption of pro-oxidant/antioxidant balance might lead to tissue 
injury. An increased arsenic concentration has been shown to be 
accompanied by increased lipid per-oxidation in animal tissues.10 
Exposure  to  sodium  arsenite  has  been  reported  to  significantly 
decrease  glutathione  (GSH)  level,  superoxide  dismutase  (SOD), 
glutathione  peroxidase  (GPx)  and  catalase  activity.9  Maiti  and 
Chatterjee11 reported that liver and kidneys have different adaptive 
cellular protective mechanism against arsenic exposure.
The current approved clinical intervention against arsenic toxicity 
is to give chelating agents which form an insoluble complex with 
arsenic  and  remove  it  from  the  burdened  tissues.  Most  of  these 
chelating agents however, suffer from serious side effects.12,13 Clinical 
reliance on meso 2,3-dimercaptosuccinic acid (DMSA), an orally 
administered chelator, has expanded greatly during the last few years 
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over the physiological pH range.27 Taurine is known to maintain 
calcium homeostasis, osmoregulation, removal of hypochlorous acid, 
and stabilizing the membranes.27 It’s potential as a chelating agent 
against  lead  poisoning  has  been  reported  by  us.28 We  concluded 
that the administration of taurine exerts no influence on blood and 
soft  tissue  lead  levels,  but  recommended  its  use  as  a  therapeutic 
intervention in lead poisoning, particularly in combination with a 
chelator. Taurine was also shown to form less stable metal complexes 
with various transition metals such as Cu+2, Ni+2, Zn+2, Fe+2, Mg+2, 
Mn+2, compared to other amino acids. Direct interaction between 
taurine and metal ions is mainly attributed to the electric association 
between metal cations and the sulfonate anion or to the interaction 
between metal ions and the nitrogen’s unshared pair of electrons.26 
The present study was thus planned to investigate the therapeutic 
efficacy  of  taurine  in  combination  with  MiADMSA  on  altered 
biochemical  variables  suggestive  of  oxidative  stress  and  arsenic 
concentration in blood and tissues post chronic arsenic exposed rats. 
Results
Data  indicative  of  alterations  in  heme  biosynthesis  pathway 
and  oxidative  stress  in  arsenic  exposed  rats  and  after  treatment 
with taurine, MiADMSA either individually or in combination, is 
shown in Table 1. Exposure to arsenic significantly decreased blood 
ALAD activity and increased ZPP level while, GSH concentration 
showed  marginal  depletion.  Administration  of  taurine  (100  mg/
kg) and MiADMSA individually, had no effect on inhibited blood 
ALAD activity, ZPP and GSH levels except for a moderate beneficial 
effect of MiADMSA when administered alone on blood ZPP levels. 
Combined administration of lower dose of taurine (50 mg/kg) with 
MiADMSA was effective in increasing blood ALAD and depleting 
ZPP level although the effects were statistically non significant. On 
the other hand, combined administration of a higher dose of taurine 
(100 mg/kg) with MiADMSA led to a more pronounced beneficial 
effects  on  ALAD  activity  and  GSH  levels  compared  to  all  other 
treatments.  Neither  MiADMSA  nor  the  combination  treatments 
with taurine were effective in reducing ZPP level towards the normal 
value.
particularly after it was approved for the clinical use against child-
hood lead poisoning by US Food and Drug Administration (FDA).14 
DMSA is one of the least toxic drugs that could be given orally; a less 
obvious benefit may also be derived as a result of DMSA’s structural 
potential to serve as an antioxidant in vivo15 however, use of DMSA 
is compromised with some limitations. Hydrophilic and lipophobic 
properties of DMSA do not allow it to pass through cell membrane. 
It was recently reported that the monoesters of DMSA might be 
more effective chelating agent for metal poisoning than DMSA.16,17 
Mono isoamyl ester of DMSA (MiADMSA) is a C5 branched chain 
ester (Fig. 1) that has been found to be more effective than DMSA 
in reducing lead, mercury and cadmium burden.13,18 Structure of 
MiADMSA comprises of straight and branched chain amyl group 
which helps in increasing its lipophilicity. Lipophilicity and molecular 
size of this new drug might be an important factors for the removal 
of arsenic from both intra-cellular sites possibly leading to better 
therapeutic efficacy.19 It has been observed that MiADMSA is more 
efficient in mobilizing brain lead than DMSA.20 It is believed that 
DMSA being relatively efficient and non-toxic chelator, MiADMSA 
should also be of greater interest particularly as a potential drug for 
chelation therapy in arsenic poisoning. One of the major drawbacks 
of chelation therapy is related to redistribution of toxic metals to other 
tissues, especially to the brain.5 No such redistribution was however, 
observed  with  MiADMSA  administration.21  Mehta  and  Flora22 
reported that administration of MiADMSA may lead to copper loss 
and also mild hepatotoxicity. It indicates greater complexing poten-
tial of DMSA monoester compared to DMSA. The depletion of 
essential metals does not necessarily result in the pronounced excre-
tion of the metal in the urine. A number of previous reports have 
indicated an increased uptake of zinc and copper with no alteration 
in urinary copper and zinc following DMSA administration.23 It has 
also been reported that chelator is relatively safe during late gesta-
tion and it does not cause any major alteration in the mothers and 
the developing pups.24 Despite a few drawbacks/side effects associ-
ated with MiADMSA, MiADMSA is being considered recently as a 
future drug of choice owing to its specificity, accessibility to intra-
cellular spaces and the absence of essential metal redistribution.22-24 
Moderate toxicity followed by administration of MiADMSA may be 
reversible after withdrawal of chelating agent. 
As mentioned above, arsenic induced oxidative stress is one of 
the  possible  mechanisms  involved  in  the  pathogenesis  of  arsenic 
poisoning. Thus, it is believed that supplementation of an antioxi-
dant during treatment should be one of the important components 
of  an  effective  arsenic  therapy.  Some  of  the  antioxidants  like 
n-acetylcysteine (NAC) have been proved to be beneficial both in 
reducing oxidative stress and arsenic burden.15 Such dual benefits of 
these chelators and/or antioxidant support their use in combination. 
This may support the theory (combination treatment) for a more 
effective treatment of arsenic poisoning compared to their individual 
treatment.
Taurine  is  a  naturally  occurring  antioxidant  and  a  drug  used 
for the treatment of diabetic polyneuropathy (structure shown in 
Fig. 1).25 It has a thiol group and found naturally in plants and 
animals. Taurine  is  a  sulphur  containing  δ-amino  acid  found  in 
millimolar  concentrations  especially  in  tissues  that  are  excitable, 
rich in membranes and generates oxidants.26 The sulfonate group 
in  taurine  is  a  strong  acid  that  makes  it  completely  zwitterionic 
Figure 1. Chemical structure of taurine and MiADMSA.Taurine protects arsenic toxicity
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alone provided most effective reversal in GSH 
and  GSSG  levels  compared  to  individual 
treatment with taurine. Co-administration of 
taurine (particularly at the higher dose) and 
MiADMSA,  on  the  other  hand,  provided 
more pronounced recovery in these variables 
compared to all other treatments (Table 4). 
Data  in  Figure  2  depicts  levels  of  GSH 
and  GSSG  in  kidneys  of  arsenic  exposed 
rats  and  following  treatment  with  taurine 
and  MiADMSA,  either  individually  or  in 
combination.  Kidney  GSH  level  decreased 
marginally while, GSSG level increased signif-
icantly on arsenic exposure. All the treatments 
were able to restore altered GSH level however 
GSSG level responded favorably only to the 
combined administration of MiADMSA and 
taurine (100 mg/kg). 
Figure  3  shows  arsenic  concentration  in  blood,  liver  and 
kidney of arsenic exposed animals and the ability of taurine, and 
MiADMSA either alone or in combination to reduce its concentra-
tion. Administration of taurine alone had no effect on arsenic levels 
while  administration  of  MiADMSA  alone  significantly  reduced 
arsenic concentration of blood, liver, and kidney. Co-administration 
of taurine at higher dose (100 mg/kg) with MiADMSA provided the 
best effects in reducing arsenic concentration from these organs than 
any other treatments. 
Material and Methods
Animals  and  treatments.  Male  wistar  albino  rats  weighing 
approximately 110–120 g were obtained from the Defence Research 
and Development Establishment (DRDE) animal facility and prior 
to  use,  were  acclimatized  for  7  days  12  h  light/dark  cycle. The 
Animal Ethical Committee of the DRDE, Gwalior, India, approved 
the protocols for the experiments. Rats were divided into two groups 
of  five  and  twenty  five  rats  each  and  were  treated  as  below  for 
24 consecutive weeks, 
Group I: Normal animals (Received normal water)
Group II: As (25 ppm, as sodium meta-arsenite, in drinking water)
After 24 weeks of arsenic exposure, animals in Group II were sub-
divided into 5 groups of five animals each and treated as below, for 
5 consecutive days:
Table 2 shows the effect of taurine and MiADMSA either indi-
vidually  or  in  combination  on  some  selected  clinical  variables  in 
blood. No significant change in the levels of RBC, Hb and HCT 
were noted however, WBC level decreased and PLT counts showed 
significant increase on arsenic exposure. None of the treatments were 
effective in influencing altered WBC and PLT levels. 
 Table 3 shows the effect of taurine and MiADMSA either indi-
vidually or in combination on blood MCV, MCHC and MCH levels 
in arsenic pre-exposed rats. All the three parameters were significantly 
decreased on arsenic exposure. Taurine and MiADMSA individually 
had no effect on these altered clinical variables. Combined adminis-
tration of a lower dose of taurine (50 mg/kg) with MiADMSA also 
had no beneficial effects on these variables while the administration 
of higher dose of taurine (100 mg/kg) with MiADMSA provided 
significant recovery in MCHC and MCH levels compared to all 
other treatments. 
The levels of hepatic GSH, GSSG, and activities of SOD and 
catalase  in  animals  exposed  to  arsenic  and  following  treatment 
with taurine, and MiADMSA, either individually or in combina-
tion, are shown in Table 4. Exposure to arsenic significantly reduced 
hepatic  GSH  level  and  increased  GSSG  concentration  while, 
liver  SOD  activity  exhibited  a  decrease  and  catalase  an  increase. 
Administration  of  taurine  was  most  effective  compared  to 
MiADMSA  administration  in  significantly  restoring  catalase  and 
SOD activities towards normal value. Treatment with MiADMSA 
Table 1   Effects of MiADMSA and taurine co-administration on some arsenic  
    sensitive biochemical variables suggestive of altered heme  
  biosynthesis pathway and oxidative stress 
  ALAD  ZPP  GSH
  (nmol/min/ml erythrocytes)  (µmol ZPP/mol heme)  (mg/ml)
Normal animals  9.86 ± 0.80*  61.0 ± 0.66*  5.00 ± 0.33*
Arsenic, 25 ppm  4.30 ± 0.17†  96.3 ± 6.11†  4.38 ± 0.62*
Taurine, 100 mg/kg  4.63 ± 0.17†  93.6 ± 1.45†  4.49 ± 0.17*
MiADMSA, 50 mg/kg  5.00 ± 0.10†  79.0 ± 3.00†  4.89 ± 0.08*
MiADMSA + Taurine, 50 mg/kg  5.60 ± 0.13†  83.3 ± 10.4†  4.84 ± 0.07*
MiADMSA + Taurine, 100 mg/kg  8.10 ± 0.70‡  85.2 ± 8.03†  5.04 ± 0.03*
ALAD, δ-aminolevulinic acid dehydratase; ZPP, zinc protoporphyrin; GSH, reduced glutathione; MiADMSA, monoisoamyl dimercaptosuc-
cinic acid; Values are mean ± SE; n = 5; *, †, ‡Means with matching symbol notations in each column are not significant at 5% level of 
significance.
Table 2  Effects of MiADMSA and taurine co-administration on some clinical hematological variables
  WBC  RBC  PLT  Hb  HCT
  (103/ µl)  (106/µl)  (106/µ)  (g/dl)  (%)
Normal animals  7.54 ± 1.76*  5.0 ± 0.88*  782 ± 98*  11.6 ± 0.21*  37 ± 5.3*
Arsenic, 25ppm   3.65 ± 0.31†  6.4 ± 0.25*  1203 ± 126†  11.9 ± 0.60*  43 ± 1.6*
Taurine, 100 mg/kg  3.25 ± 0.11†  7.2 ± 0.29*  918 ± 64†  13.2 ± 0.36*  47 ± 1.1*
MiADMSA, 50 mg/kg  2.95 ± 0.61†  6.7 ± 0.28*  1227 ± 75†  12.3 ± 0.01*  45 ± 0.7*
MiADMSA + Taurine 50 mg/kg   3.75 ± 0.83†  6.7 ± 0.26*  1012 ± 191†  12.4 ± 0.56*  45 ± 1.7*
MiADMSA + Taurine 100 mg/kg   2.82 ± 0.64†  5.7 ± 1.05*  1623 ± 344†  12.2 ± 0.34*  38 ± 5.8*
WBC, white blood cells; RBC, red blood cells; PLT, platelet; Hb, Hemoglobin; HCT, hematocrit; MiADMSA, monoisoamyl dimercaptosuccinic acid; Values are mean ± SE; n = 5; *, †Means with matching symbol notations 
in each column are not significant at 5% level of significance.Taurine protects arsenic toxicity
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For blood and tissues metal determination, wet tissue weight and 
volume of blood was recorded. After digestion with concentrated 
nitric acid using a microwave digestion system (model MDS-2100, 
CEM, USA), samples were brought to a constant volume and deter-
mination of tissue arsenic contents was performed using a hydride 
vapor generation system fitted with an atomic absorption spectro-
photometer (AAS, Perkin Elmer model AAnalyst 100). 
Discussion
The  present  study  concludes  beneficial  role  of  taurine  when 
administered along with MiADMSA in providing effective reversal 
of number of arsenic sensitive biochemical variables suggestive of 
oxidative  stress  and  altered  heme  biosynthesis  pathway. The  data 
provides  some  interesting  observations  for  suggesting  an  effective 
treatment  for  cases  of  chronic  arsenic  poisoning.  We  understand 
that extrapolating the animal data to human cases has its limitations 
particularly for the fact that similar signs and symptoms following 
chronic arsenic exposure in animal models are difficult. In human 
cases signs of chronic toxicity appear after long term exposure to 
a  low  dose  of  arsenic  and  thus  we  selected  comparatively  higher 
dose of arsenic in the present study in animal model for achieving 
the few similar effects which are seen in human cases. Shila et al.37 
selected 100 ppm dose of arsenite for a 8 weeks exposure in rats in 
order to evaluate alterations in glutathione level and its response to 
lipoic acid. For MiADMSA dose protocol, a dose of 50 mg/kg dose 
through oral route has been reported by us in the previous studies 
to be ideal to achieve the best therapeutic effects following arsenic 
Group IIA: saline
Group IIB: Taurine (100 mg/kg, i.p., once 
daily)
Group IIC: MiADMSA (50 mg/kg, orally 
once daily)
Group IID: MiADMSA (same as Gr. II C) 
+ Taurine, 50 mg/kg, i.p.
Group IIE: MiADMSA (same as Gr. II C) 
+ Taurine, 100 mg/kg, i.p.
Arsenic exposure was stopped during the 
course of chelation treatment. The doses for 
MiADMSA and taurine were selected based 
on  previously  reported  studies.28,29  Doses 
of  chelating  agents  and  taurine  were  given 
6 hours apart, on each day. Throughout the 
experiment the animals were kept on standard 
pellet diet (Amrut Feeds, Pranav Agro, New Delhi, metal contents 
of diet, in ppm dry weight Zn 45, Cu 10, Mn 55, Fe 70, Co 5). 
Animals were sacrificed under light ether anesthesia 48h after the 
last dose. Blood was collected by cardiac puncture in heparinized 
tubes. Liver and kidney were removed, rinsed in cold saline, blotted, 
weighed  and  used  for  various  biochemical  variables  and  metal 
analysis. Half portion of the liver and one of the kidneys from each 
rat was processed immediately for biochemical estimation and the 
remaining was stored at -20˚C before wet acid digestion with HNO3 
for estimation of arsenic contents.
Biochemical  assays. The  activity  of  blood  ALAD  was  assayed 
according to the procedure of Berlin and Schaller.30 Zinc protopor-
phyrin (ZPP) was determined in a drop of blood with the help of 
a haematoflurometer (Model 2060, Aviv, Lakewood, USA) and a 
calibrated glass slide.31 For the determination of blood GSH concen-
tration, the method of Ellman32 was followed, while for tissue (liver 
and kidneys) GSH and GSSG estimation, the procedure of Hissin 
and Hilf was followed.33 Superoxide dismutase (SOD) activity in 
liver was assayed spectrophotometrically as described by Durak et 
al.34 Catalase activity was assayed following the procedure of Aebi35 
at room temperature. The molar extinction coefficient of 43.6 M 
cm-1 was used to determine CAT activity. One unit of activity is 
equal to the moles of H  2O2 degraded/min/mg protein. Tissue lipid 
oxidazibility  was  measured  by  shaking  the  liver  homogenate  in 
150 mM KCl, 0.025 M Tris-HCl buffer (pH 7.5) for 30 min at 37˚C 
and measuring the lipid oxidation formed with the thiobarbituric 
acid reaction.36 
Table 3   Effects of MiADMSA and taurine co-administration on some clinical  
  hematological variables
  MCV   MCHC  MCH
  (fl)  (g/dl)  (pg)
Normal animals  76.9  ±  6.52*  34.8 ± 0.50*  28.4 ± 0.82*
Arsenic, 25 ppm  68.5 ± 0.97†  26.9 ± 0.38†  18.4 ± 0.46†
Taurine, 100 mg/kg   64.9 ± 1.49†  28.1 ± 0.56†  18.2 ± 0.46†
MiADMSA, 50 mg/kg  68.1 ± 2.01†  27.2 ± 0.47†  18.5 ± 0.88†
MiADMSA + Taurine 50 mg/kg   68.3 ± 1.22†  27.1 ± 0.69†  18.5 ± 0.29†
MiADMSA + Taurine 100 mg/kg  68.4 ± 3.36†  34.9 ± 6.94*  24.7 ± 6.41*
MCV, mean cell volume; MCHC, mean cell hemoglobin concentration; MCH, mean cell hemoglobin; MiADMSA, monoisoamyl dimercaptosuc-
cinic acid; Values are mean  ±  SE; n = 5; *, †Means with matching symbol notations in each column are not significant at 5% level of 
significance.
Table 4  Effects of MiADMSA and taurine co-administration on some biochemical variables suggestive 
  of hepatic oxidative stress 
  Catalase  SOD  GSH  GSSG
  (μmoles/min/mg protein)  (units/min/mg protein)  (mg/ml)  (mg/ml)
Normal animals  3.37 ± 0.34*  0.49 ± 0.03*  14.4 ± 1.1*  0.84 ± 0.06*
Arsenic, 25 ppm  7.36 ± 0.62†  0.18 ± 0.03†  8.5 ± 1.2†  1.97 ± 0.47†
Taurine, 100 mg/kg  2.14 ± 0.51*  0.34 ± 0.03‡  8.1 ± 1.0†  0.50 ± 0.03‡
MiADMSA, 50 mg/kg  9.19 ± 1.00†  0.26 ± 0.01†  9.7 ± 0.8†  0.89 ± 0.01*
MiADMSA + Taurine 50 mg/kg  2.98 ± 0.29*  0.35 ± 0.01‡  9.5 ± 0.9†  0.72 ± 0.14*
MiADMSA + Taurine, 100 mg/kg  5.80 ± 0.29‡  0.22 ± 0.01*  11.7 ± 0.6‡  0.77 ± 0.03*
SOD, superoxide dismutase; GSH, reduced glutathione; GSSG, oxidized glutathione; MiADMSA, monoisoamyl dimercaptosuccinic acid; Values are mean  ±  SE; n = 5; *, †, ‡Means with matching symbol notations in 
each column are not significant at 5% level of significance.Taurine protects arsenic toxicity
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of  100  mg/kg  were  noted  when  it  was 
administered  along  with  MiADMSA  on 
biochemical  variables  suggestive  of  oxida-
tive  stress.  The  reversal  in  the  inhibited 
ALAD  activity  following  treatment  with 
MiADMSA might be attributed to the availability of thiol groups 
(Fig. 1). Co-administration of MiADMSA with taurine (100 mg/
kg) led to a more pronounced recovery in arsenic-induced oxida-
tive injury compared to the individual effects of these drugs. These 
beneficial  effects  might  be  due  to  (i)  depletion  of  body  arsenic 
burden by MiADMSA and/or (ii) antioxidant action of taurine.28 
Increased catalase activity and decreased SOD activity in liver was 
also noted following arsenic exposure. Role of taurine in maintaining 
GSH levels and increasing the status of antioxidant enzymes (SOD, 
Catalase and GPX) by directly scavenging superoxide radicals and 
reducing cellular damage caused by free radicals have been reported 
earlier  in  lead  exposed  animals.46  It  has  been  demonstrated  that 
taurine acts as an antioxidant in vivo and in vitro studies.47 The 
mechanism of the possible antioxidative effects of taurine is unclear, 
but it has been suggested that the same is related to free radical 
scavenging activity of taurine.48 The free sulphydryl group in taurine 
seems to play a significant role as a ROS scavenger. Taurine is neither 
metabolized  nor  incorporated  into  cellular  proteins  in  mammals 
suggesting  ready  availability  of  sulfhydryl  moiety  in  cytosol.27,49 
Antioxidant  potential  of  taurine  has  also  attributed  to  its  ability 
to restore metal induced depletion of membrane Na+, K+-ATPase 
activity.50 Besides the above, mechanism for the antioxidant effect 
of taurine can also be explained as its direct action to quench and 
detoxify some reactive intermediate such as hypochlorous acid gener-
ated by myeloperoxidase,50 nitric oxide,51 and H2O2
52 and indirectly 
via  protecting  cells  through  intercalating 
into the membrane and stabilizing it.53 The 
membrane  protecting  activity  of  taurine 
is suggested to be related to its action on 
permeability  to  ions  and  water.47  In  this 
exposure including depletion of intracellular arsenic.38 Few recent 
studies  reported  the  superior  efficacy  of  monoisoamyl  DMSA 
(MiADMSA)  and  mono-n-amyl  DMSA  in  protecting  the  mice 
from  the  lethal  effects  of  arsenic  and  in  reducing  body  arsenic 
burden.38,39 
Reactive oxygen species are thought to contribute to the patho-
genesis of arsenic toxicity.40,41 Results from the present study also 
suggest that some of the toxic effects of arsenic could be attributed to 
the arsenic induced oxidative stress. A significant inhibition of blood 
ALAD and GSH level and an increase in ZPP level was noted in the 
present study. It is well known that arsenic affects the haematopoi-
etic system by inhibiting the haem bio-synthesis. The enzyme that is 
sensitive to the toxic effects of arsenic is probably δ-aminolevulinic 
acid dehydratase (ALAD). ALAD is a sulfhydryl-containing enzyme 
involved in the heme synthesis pathway, and its inhibition can be 
attributed to the binding of arsenic with sulfhydryl groups. Arsenic 
has got a high affinity for -SH group and it binds with reduced 
glutathione (GSH). Inhibition of ALAD enzyme by arsenic led to 
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exposed  rats.  Figure  shows  oxidative  stress 
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(100  mg/kg)  and  MiADMSA.  GSH,  reduced 
glutathione; GSSG, oxidized glutathione. Values 
are mean ± SE; n = 5. *,†,‡Means with matching 
symbol notations in each column are not signifi-
cant at 5% level of significance
Figure  3.  Effects  of  MiADMSA  and  taurine 
co-administration  on  arsenic  concentration  in 
blood and soft tissues. Figure shows significantly 
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combined administration of taurine (100 mg/kg) 
and  MiADMSA.  MiA,  monoisoamyl  dimercap-
tosuccinic acid; As, arsenic. Values are mean ± 
SE;  n  =  5.  *,†,‡,§Means  with  matching  symbol 
notations in each column are not significant at 
5% level of significance.Taurine protects arsenic toxicity
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study, a direct correlation between arsenic concentration and tissue 
oxidative injury was noted. Depletion in tissue oxidative stress was 
accompanied  by  a  decrease  in  tissue  arsenic  level.  Similar  obser-
vations  were  noted  where  taurine  administration  protected  lead 
induced  oxidative  stress  in  rats.28  Taurine  supplementation  also 
provided  significant  recovery  in  depleted  SOD  activity.  SOD,  a 
metalloprotein accomplishes its antioxidant function by protecting 
the cells against the toxic effects of O2- by catalyzing its dismutation 
reactions. A significant effect of taurine on liver and kidney GSSG 
was observed, while only a marginal protection was noticed on liver 
and kidney GSH after taurine administration. Although, it has been 
reported recently that taurine has a protective effect against thioacet-
amide hepatotoxicity in rats.54 and also decreases oxidative stress.55 
Another new and interesting observation in the present study was 
that  taurine  at  the  dose  of  100  mg/kg  when  administered  along 
with MiADMSA provided more pronounced depletion of arsenic 
concentration in blood, liver and kidneys. This suggests that the 
antioxidative capacity of taurine becomes most effective only when 
it is administered along with the thiol chelators or taurine might 
be facilitating the entry of chelator to the intracellular sites thereby 
reducing arsenic concentration. 
The results thus lead to conclude the beneficial role of taurine 
when administered along with a thiol chelator but still it remains 
to be seen if: (i) taurine is a better antioxidant than other avail-
able  antioxidants  in  providing  significant  clinical  recovery;  (ii)  a 
dose dependent study using a higher dose of taurine need to be 
attempted; (iii) the exact mechanism of action of taurine needs to 
be elucidated. 
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